SCHEMBL2473570

SCHEMBL2473570

Cc1cc([N+](=O)[O-])cc(C)c1-n1cccc(Br)c1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.41
CYP3A4 P08684 3/20 0.41
TDP1 Q9NUW8 2/20 0.41
TSHR P16473 5/20 0.40
POLB P06746 1/20 0.39
KMT2A Q03164 2/20 0.37
MEN1 O00255 1/20 0.37
GPR35 Q9HC97 1/20 0.36
ACHE P22303 1/20 0.36
CHEK1 O14757 1/20 0.36
PIM1 P11309 1/20 0.36
LIMK1 P53667 1/20 0.36
TYRO3 Q06418 1/20 0.36
MAPK14 Q16539 1/20 0.36
CLK4 Q9HAZ1 1/20 0.36
NQO2 P16083 1/20 0.35
MAPK1 P28482 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 1/20 0.33
GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2473608 0.83 ALDH1A1 (0.46) ALDH1A1CYP3A4TDP1TSHRPOLB
SCHEMBL3644238 0.83 ALDH1A1 (0.43) ALDH1A1CYP3A4TDP1TSHRPOLB
SCHEMBL3424022 0.81 ALDH1A1 (0.43) ALDH1A1CYP3A4TDP1TSHRPOLB
SCHEMBL2477291 0.80 ALDH1A1 (0.39) ALDH1A1CYP3A4TDP1TSHRPOLB
SCHEMBL2471712 0.79 RAB9A (0.38) ALDH1A1CYP3A4TDP1TSHRPOLB
SCHEMBL27909201 0.77 RECQL (0.45) ALDH1A1TDP1TSHRPOLBKMT2A
SCHEMBL15929085 0.77 MAPT (0.36) ALDH1A1CYP3A4TDP1TSHRPOLB
SCHEMBL2590559 0.77 CYP1A2 (0.43) ALDH1A1CYP3A4TDP1TSHRPOLB
SCHEMBL12179486 0.73 ALDH1A1 (0.39) ALDH1A1KMT2AMEN1L3MBTL1LMNA
SCHEMBL2471403 0.72 PDE7A (0.48) ALDH1A1KMT2AMEN1CHEK1PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2563762-B1 METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE BAYER IP GMBH (DE) 2015-07-22 EP disclosed
EP-2563762-B1 METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE BAYER IP GMBH (DE) 2015-07-22 EP disclosed
CN-102906071-B Method for producing substituted pyridin-2-one BAYER IP GMBH 2015-03-18 CN disclosed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-8846934-B2 Substituted oxazolidinones and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-09-30 US disclosed
US-8802860-B2 Method for producing substituted pyridin-2-one BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-08-12 US disclosed
US-8802860-B2 Method for producing substituted pyridin-2-one BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-08-12 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-02-27 US disclosed
WO-2011134963-A1 METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2011-11-03 WO disclosed
EP-2173744-B1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION Bayer Pharma AG (DE) 2011-10-05 EP disclosed
EP-2173744-B1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION Bayer Pharma AG (DE) 2011-10-05 EP disclosed
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-10-14 US disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2010-07-22 US disclosed
WO-2008155033-A1 SUBSTITUTED (OXAZOLIDINON-5-YL-METHYL) -2-THIOPHENE-CARBOXAMIDES AND USE THEREOF IN THE FIELD OF BLOOD COAGULATION BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140057951-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L ALDH1A1 523/4885CYP3A4 54/4885TDP1 2020/4885
US-20100184740-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L ALDH1A1 523/4885CYP3A4 54/4885TDP1 2020/4885
US-20100261759-A1 SUBSTITUTED OXAZOLIDINONES AND THEIR USE XDH, MPL, OXA1L ALDH1A1 523/4885CYP3A4 54/4885TDP1 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.